# Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

> **NCT06474481** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- FL

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Prednisone
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT06474481
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2027-12
- **Final completion:** 2029-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06474481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06474481, "Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06474481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*